top of page


För Nyheter och Media

FrostPharma strengthens product portfolio with deal of 5 additional hospital pharmaceuticals

FrostPharma has entered an agreement with STEROP, bringing 5 additional products to the current FrostPharma portfolio. The deal encompasses commercial rights, including distribution and market authorization rights for the included products.

“FrostPharma has showed a very strong development since the start in 2017 and we have continuously reinvested the profits to build the portfolio with value-added products, allowing us to bring beneficial treatment options across multiple disease areas to our markets. With this agreement we will further strengthen the long-term outlook for FrostPharma’s future growth in all the Nordic countries.”, says CEO Cecilia Bröms-Thell.

The expected sales for the products included in the agreement with STEROP will contribute significantly to the top-line growth of FrostPharma already in the near-term perspective.

About FrostPharma AB:

FrostPharma is an entrepreneurial Swedish pharmaceutical company specializing in the commercialization of value-added products.

Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, throughout the Nordic countries and beyond. The key to our success is using our extensive in-house commercialization competence to match specific patient and health care needs with relevant products.


STEROP is a Belgian pharmaceutical group with the ambition to be a global leading player in the field of essential medicines and innovative products.

0 kommentarer

Senaste inlägg

Visa alla

FrostPharma enters the hematology area in the Nordics

FrostPharma takes another step in its growth journey of becoming a leading European Specialty Pharma company, by being authorized by IDEOGEN as the exclusive Nordic representative to support patient a


bottom of page